Buy Rating for Silexion Therapeutics Driven by Promising SIL-204 Developments and Market Expansion

Maxim Group analyst Naz Rahman reiterated a Buy rating on Silexion Therapeutics (SLXN – Research Report) yesterday and set a price target of $5.00.

Naz Rahman has given his Buy rating due to a combination of factors surrounding Silexion Therapeutics’ promising developments with their SIL-204 therapy. The company is expanding the development of SIL-204, a KRAS-targeting siRNA therapy, to treat both locally advanced and metastatic pancreatic cancer. This expansion is based on positive preclinical data showing the therapy’s potential in reducing metastasis and demonstrating anti-tumor activity.
Furthermore, the previous formulation of SIL-204, known as LODER, showed significant efficacy in clinical trials, improving overall survival and reducing the risk of death in patients with locally advanced pancreatic cancer. The company’s strategic plans include initiating Phase 2b/3 studies and engaging with regulatory authorities, which are expected to enhance the therapy’s market potential. These factors, combined with a calculated valuation approach, support the Buy rating with a 12-month price target of $5.00.